Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer


Bladder Urothelial Carcinoma | Distal Urethral Carcinoma | Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter | Proximal Urethral Carcinoma | Recurrent Bladder Carcinoma | Recurrent Prostate Carcinoma | Recurrent Urethra Carcinoma | Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter | Regional Urothelial Carcinoma of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Stage IV Prostate Cancer | Stage IV Urethral Cancer | Ureter Carcinoma

What is the purpose of this trial?

This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether gemcitabine hydrochloride and cisplatin are more effective when given with or without bevacizumab in treating patients with urinary tract cancer.

Participation Guidelines

18 Years - N/A

Click here for detailed information about who can participate in this trial.

National Cancer Institute (NCI)
July 2009
Last Updated:
December 8, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00942331